title: Improved bioavailability of a new oral preparation of medroxyprogesterone acetate.
abstract: Medroxyprogesterone acetate (MPA) is widely used in the hormonal therapy of breast cancer. So far, oral formulations of MPA commercially available present a very low bioavailability, with a less than 10% extent of oral absorption. A new oral preparation of MPA has been recently developed. Based on a pilot study, an open, randomized, crossover trial has been performed on 22 breast and endometrial cancer patients to evaluate the relative bioavailability of this new oral formulation (200-mg sachet, twice daily) as compared with a standard formulation (Farlutal, 500-mg tablet, twice daily). The bioavailability evaluation was mainly based on the area under the curve measured between two administrations at steady state, after 15 days of continuous therapy. Wide interpatient variability of MPA plasma levels after oral MPA administration was confirmed. The MPA plasma levels were higher in patients treated with the new formulation than in patients treated with Farlutal. The relative bioavailability of the new preparation was 3.5 times higher than that of the standard. This new formulation represents a great improvement in the extent of oral absorption of MPA and could lead to better management of hormone-responsive tumors by hormonal therapy.
authors.affiliation: Centre Antoine Lacassagne, Nice, France.
authors.forename: M C
authors.initials: MC
authors.lastname: Etienne
authors.forename: G
authors.initials: G
authors.lastname: Milano
authors.forename: N
authors.initials: N
authors.lastname: René
authors.forename: M S
authors.initials: MS
authors.lastname: Benedetti
authors.forename: C
authors.initials: C
authors.lastname: Efthymiopoulos
authors.forename: M L
authors.initials: ML
authors.lastname: Vo Van
authors.forename: P
authors.initials: P
authors.lastname: Hurteloup
authors.forename: P
authors.initials: P
authors.lastname: Montcuquet
authors.forename: M
authors.initials: M
authors.lastname: Frenay
authors.forename: M
authors.initials: M
authors.lastname: Namer
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D001682:Biological Availability; D001943:Breast Neoplasms / Q000378:metabolism*; D005260:Female; D006801:Humans; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D017258:Medroxyprogesterone Acetate; D008875:Middle Aged; D014594:Uterine Neoplasms / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone